

Therapeutic Plan: Device Selection. 1 : Utilize wearable insulin delivery systems such as the Omnipod 5 Automated Insulin Delivery System or Medtronic's MiniMed systems. Intervention: Compare the wearable insulin delivery system with standard care (e.g., continuous subcutaneous insulin infusion [CSII] or multiple daily injections [MDI]). These devices integrate continuous glucose monitoring (CGM) data to adjust insulin delivery automatically. 2. Patient Eligibility Include patients aged years and older with Type 1 Diabetes (T1D), focusing on both adults and children to assess efficacy across different age groups. – Time in Range (TIR): The percentage of time blood glucose levels are within the target range (70–180 mg/dL) ? Hemoglobin A1c (HbA1c) Levels: To assess overall glycemic control ? Monitoring Parameters . Track key outcomes such as: ? 3.4.5